Leading Biosciences Company’s 2010 Performance Characterized by Cutting-Edge Technology Advancements and Significant Growth
IRVING, TX, January 18, 2011 — Caris Life Sciences, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest-quality anatomic pathology, molecular profiling, and blood-based diagnostic services, today announced key highlights of its 2010 performance. The importance of high-quality diagnosis in driving patient care was underscored by the company’s significant growth. Caris’ progress sets the stage to have a transformative influence on healthcare in 2011, through the introduction of blood tests for the early detection of cancer and other complex diseases, based on its revolutionary Carisome™ circulating microvesicle (cMV) technology.
Specific highlights from 2010 include:
Caris’ focus on providing patients and physicians with the highest-quality diagnostic services has fueled rapid increases in patients diagnosed and job creation at the company. This growth includes:
Service Line Expansion:
Caris brings a long-standing commitment to new technologies that bring precise and targeted diagnostics, prognostics and theranostics to physicians and their patients. During 2010, this commitment was manifest across all three principal service lines:
Carisome Microvesicle Technology
CarisPath Expert Pathology Services:
Caris Target Now Molecular Profiling:
Research & Development:
Caris’ scientific and medical experts are dedicated to their specialties and to contributing to the advancement of science and improved patient care worldwide. 2010 highlights of this dedication include:
Expertise & Infrastructure:
In order to support the vastly increased demand for Caris’ services, 2010 investments centered on increasing the company’s expert personnel and infrastructure. These investments included:
“This was an important year as it was the culmination of our transition from a small anatomic pathology practice into a global life sciences company. We attracted and hired the right people to accomplish this transition. We added several essential new functions that did not exist within our company, including regulatory, intellectual property, marketing, medical affairs and clinical affairs. And, we expanded our research and development efforts and our geographic footprint internationally,” said David D. Halbert, Chairman and CEO.
“We developed a proprietary technology that creates the opportunity for accurate diagnosis early — so that we can get patients on the right treatment sooner, dramatically improving their chances for recovery,” continued Halbert. “As a result, we believe this technology will significantly contribute to the relief of suffering, which is our ultimate goal as a company. With this goal in mind, we have significantly increased our investment in the commercialization of our revolutionary Carisome circulating microvesicle technology. This groundbreaking, patented, blood-based platform will be the basis for many tests that we believe will transform healthcare by providing patients and their doctors valuable information at the earliest stages of disease – and all from a simple blood test.”
About Caris Life Sciences
Caris Life Sciences, a leading biosciences company, specializes in the development and commercialization of the highest quality anatomic pathology, molecular profiling, and blood-based diagnostic technologies, in the fields of oncology, dermatopathology, hematopathology, gastrointestinal pathology and urologic pathology. The company provides academic-caliber consultations for thousands of patients a day, through its industry-leading team of expert, subspecialty pathologists. Caris also offers advanced molecular analyses of patient samples through prognostic testing services and genomic, transcriptomic, and proteomic profiling to assist physicians in their treatment of cancer. Currently, Caris is developing a series of blood tests utilizing the patented Carisome™ platform — a proprietary, blood-based testing technology for diagnosis, prognosis, and theranosis of cancer and other complex diseases. The company is headquartered in the Dallas metroplex, and operates laboratories at the headquarters, as well as in the Phoenix and Boston metro areas.
Caris Life Sciences